MR/CT February 2026

Bayer Presents Phase III Cardiac MRI Data for Low-Dose Gadoquatrane

Bayer has reported positive Phase III subgroup data for its investigational low-dose MRI contrast agent gadoquatrane in cardiac MRI. The results, presented at SCMR 2026, support efficacy and safety with a 60% reduction in gadolinium dose compared to standard macrocyclic agents.

Guerbet Highlights Centenary and Imaging Portfolio at ECR 2026

At ECR 2026 in Vienna, Guerbet will mark its 100th anniversary while presenting developments across contrast-enhanced MRI, real-world evidence, and international collaboration

Rewriting the Standard of Care: How Cardiac CTA Is Transforming Outcomes From Diagnosis to Prevention — and Toward Asymptomatic Screening

RSNA 2025 made one thing unmistakably clear: Cardiac CT angiography (CCTA) has reached a turning point—and it is beginning to redefine how we detect and prevent heart disease.

Bayer to Present Phase III Gadoquatrane Data at ECR 2026

Bayer will present new Phase III clinical data for its investigational low-dose MRI contrast agent gadoquatrane at ECR 2026 in Vienna.

Planmed XFI Weight-Bearing CT Earns CE MDR Certification

Planmed has received CE marking under the EU Medical Device Regulation (MDR) for its Planmed XFI weight-bearing cone-beam CT system.